BioCentury
ARTICLE | Company News

Horizon acquires rare eye disease therapy

May 11, 2017 10:21 PM UTC

Horizon Pharma plc (NASDAQ:HZNP) acquired single-asset company River Vision Development Corp. (New York, N.Y.) and its Grave's eye disease candidate teprotumumab (RV001). River Vision received $145 million up front and is eligible for milestones and earn-out payments. Horizon declined to disclose additional financial terms.

Horizon plans to begin a Phase III trial of teprotumumab next half, and hopes to submit a BLA for the candidate in 2H19. The human mAb targeting the insulin-like growth factor-1 (IGF-1) receptor (IGF1R) has breakthrough therapy and Orphan Drug designations from FDA...